Abstract:BCR-ABL kinase inhibition is an effective strategy for the treatment of chronic myeloid leukemia (CML). Herein, we report compound 3a-P1, bearing a difluoro-indene scaffold, as a novel potent pan-inhibitor against BCR-ABL mutants, including the most refractory T315I mutant. As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively. 3a-P1 displayed a good safety profile in a battery of assays, including single-dose toxicity, hERG K+, and genotoxicity. It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL). Importantly, 3a-P1 demonstrated a higher potency than ponatinib in a mice xenograft model of BaF3 harboring BCR-ABLT315I. Overall, the results indicate that 3a-P1 is a promising drug candidate for the treatment of CML to overcome the imatinib-resistant T315I BCR-ABL mutation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00082?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00082</a>.Synthesis of compounds 17a–e, crystal data for compound 29, SFC report for compounds 3a and 3b, and the determination of the absolute configuration of compound (S)-23 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_002.csv">CSV</a>)X-ray crystal structure data for compound 29 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_003.cif">CIF</a>)This article has not yet been cited by other publications.

Inhibitory Effect of the Anthelmintic Drug Pyrvinium Pamoate on T315I BCR-ABL-positive CML Cells

The Antiproliferation Effect of Berbamine on K562 Resistant Cells by Inhibiting NF‐κB Pathway

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

The Novel Anticancer Agent JNJ-26854165 is Active in Chronic Myeloid Leukemic Cells with Unmutated BCR/ABL and T315I Mutant BCR/ABL Through Promoting Proteosomal Degradation of BCR/ABL Proteins

Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia

Abstract 1602: Co-targeting mitochondria and nucleotide metabolism in T315I-BCR-ABL myeloid leukemia for therapy

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia

Deciphering the Role of Pyrvinium Pamoate in the Generation of Integrated Stress Response and Modulation of Mitochondrial Function in Myeloid Leukemia Cells through Transcriptome Analysis

Pseudolaric Acid B Induces Mitotic Arrest and Apoptosis in Both Imatinib-Sensitive and -Resistant Chronic Myeloid Leukaemia Cells.

Anthelmintic Niclosamide Suppresses Transcription of BCR-ABL Fusion Oncogene Via Disabling Sp1 and Induces Apoptosis in Imatinib-Resistant CML Cells Harboring T315I Mutant

Screening and Activity Evaluation of Novel BCR-ABL/T315I Tyrosine Kinase Inhibitors

Discovery of a Candidate Containing an (S)-3,3-difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1h-inden Scaffold As a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.

Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation

Effective Killing of Gleevec-resistant CML Cells with T315I Mutation by a Natural Compound PEITC Through Redox-Mediated Mechanism.

Targeting The Imatinib-Resistant Bcr-Abl T315i Mutation In Chronic Myeloid Leukemia Through A Novel Bcr-Abl Inhibitor

Anthelmintic Pyrvinium Pamoate Blocks Wnt/β-catenin and Induces Apoptosis in Multiple Myeloma Cells.

Abstract 4158: Targeting the Imatinib-Resistant BCR-ABL T315I Mutation in Chronic Myeloid Leukemia Through a Novel BCR-ABL Inhibitor

Abstract 3915: PBA2, a dual BCR-ABL and GSK3βkinases inhibitor, represses a wide array of Imatinib resistant cell lines in chronic myeloid leukemia

PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation

Discovery of a Candidate Containing an ( S )-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1 H -inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia

Bortezomib Induces Cell Apoptosis and Increases the Efficacy of Α PD-1 in BCR::ABL T315I Mutation CML by Targeting UBE2Q1